Tinearity is a tax-free benefit!
Duearity's assessment is that Tinearity G1 can be a deductible cost for employers
Duearity AB has commissioned a tax-law investigation that aims to investigate whether Tinearity G1 can be classified as a tax-free benefit. Duearity's assessment is that Tinearity G1 can be a deductible cost for employers and a tax-free benefit for the employee according to the provisions on preventive treatment and rehabilitation in the Income Tax Act.
People who are bothered by tinnitus can request to have a Tinearity G1 paid for by their employer.
The employer has a great responsibility to be responsible for work life-oriented rehabilitation measures and preventive treatment measures in order for an employment to continue. The measures must apply to an employee who has an increased risk of illness that can be expected to lead to reduced work ability. Measures that are put in place to prevent a potential inability to work at a later stage are thus covered by the regulations. For it to be a tax-free benefit for the employee, it is enough that the measure is classified as preventive treatment or rehabilitation.
In Sweden, 15-20% of the population has tinnitus
- Tinnitus affects a large number of people in Sweden. For example, tinnitus leads to impaired night sleep and depression, which in turn affects the employee's well-being and work performance. That Tinerity G1 can be considered a tax-free benefit can be of great benefit to all those who do not have the opportunity to pay for the product themselves, while at the same time it can benefit the employer, says Fredrik Westman, CEO of Duearity AB.
The tax legal investigation has been carried out by a tax lawyer. The reason for the completed investigation is that Duearity has received requests from both employers and employees if the employer can purchase a Tinearity G1 for the employee.
Duearity's assessment is based on the investigation that Tinearity G1 can be a deductible cost for employers and a tax-free benefit for the employee according to the provisions on preventive treatment and rehabilitation in the Income Tax Act.
For further information, please contact
Fredrik Westman, CEO
+46 738 145 215
fredrik.westman@duearity.com
www.duearity.com
About Duearity AB
Duearity is a medtech company that develops and produces solutions with the aim of alleviating symptoms and making everyday life easier for those who suffer or are bothered by tinnitus. With a deep understanding of the people who have problems with tinnitus, the Company with intelligent solutions will give these people the opportunity to fully enjoy life.
The company will offer the products Tinearity G1 and Tinearity-AI. Tinearity G1 is CE marked and sold within the EU. The product transmits white noise using non-invasive Bone Conduction Technology to the inner ear to relieve symptoms. Tinearity-AI is under development and will use artificial intelligence to help people predict the symptoms and manage their problems. The company is listed on Nasdaq First North and has its seat in Malmö.
www.duearity.com.
The company's Certified Adviser is Svensk Kapitalmarknadsgranskning AB (SKMG).
Attached files
